Please login to the form below
Fraxiparine
This page shows the latest Fraxiparine news and features for those working in and with pharma, biotech and healthcare.
GSK sells another chunk of South Africa's Aspen
GSK has a longstanding relationship with Aspen, which included the sales of its thrombosis treatments products Arixtra (fondaparinux sodium) and Fraxiparine (nadroparin) to the South African firm in 2012 in a
Latest news
-
GSK plans to sell off older products
It has already started disposing of some other assets, for example selling anticoagulants Arixtra (fondaparinux sodium) and Fraxiparine (nadroparin) to South Africa's Aspen in a £700m deal last year.
-
GSK cashes in its stake in Africa's Aspen
Last year, Aspen took control of a GSK generic drugs unit in Australia, while in October it bought a GSK plant in France and thrombosis treatments Arixtra (fondaparinux sodium) and Fraxiparine
-
GSK sells off anticoagulants for £700m
Fraxiparine is also used to treat blood clots, and has consistently achieved revenues of more than £200m for the last few years. ... potential. He said: “Arixtra and Fraxiparine are established products that have consistently delivered strong revenues.
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
Pharma deals during November 2013
divesting an extensive range of Australian products and from selling global rights to Arixtra and Fraxiparine (excluding China, India and Pakistan) in September 2013.
-
Deal Watch table for September 2013
840. GSK / Aspen Pharmacare. Acquisition of assets. 2. Arixtra and Fraxiparine - anti-thrombotic agents.
-
Pharma deals during September 2013
GSK also received $700m from the sale of two thrombosis drugs (Arixtra and Fraxiparine), to Aspen Pharmacare, South Africa's largest drug maker.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
- HCP ENGAGEMENT STUDY: Pharma shifts top priority to HCP insights and impact metrics
- AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
- BMS shares positive phase 3 results for Opdivo/Yervoy combination in colorectal cancer
- Stanford Medicine researchers find blood tests help predict organ failure
- GSK and GCOA report reveals global inequities in adult immunisation uptake
- A “Leaky Pipeline” and the Loss of Talented Female Physicians
No results were found
PMHub
Nucleus Global
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 950 experts delivering world-class...
Latest intelligence
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
